SG11202107844UA - Methods for treating symptoms and disorders associated with lysosomal storage diseases - Google Patents
Methods for treating symptoms and disorders associated with lysosomal storage diseasesInfo
- Publication number
- SG11202107844UA SG11202107844UA SG11202107844UA SG11202107844UA SG11202107844UA SG 11202107844U A SG11202107844U A SG 11202107844UA SG 11202107844U A SG11202107844U A SG 11202107844UA SG 11202107844U A SG11202107844U A SG 11202107844UA SG 11202107844U A SG11202107844U A SG 11202107844UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- disorders associated
- lysosomal storage
- storage diseases
- treating symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800996P | 2019-02-04 | 2019-02-04 | |
| US201962851433P | 2019-05-22 | 2019-05-22 | |
| US201962894167P | 2019-08-30 | 2019-08-30 | |
| US201962937618P | 2019-11-19 | 2019-11-19 | |
| US202062962647P | 2020-01-17 | 2020-01-17 | |
| PCT/US2020/016441 WO2020163245A1 (en) | 2019-02-04 | 2020-02-03 | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202107844UA true SG11202107844UA (en) | 2021-08-30 |
Family
ID=69743942
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107842QA SG11202107842QA (en) | 2019-02-04 | 2020-02-03 | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
| SG11202107844UA SG11202107844UA (en) | 2019-02-04 | 2020-02-03 | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107842QA SG11202107842QA (en) | 2019-02-04 | 2020-02-03 | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220023273A1 (en) |
| EP (2) | EP3920913A1 (en) |
| JP (2) | JP2022520747A (en) |
| KR (2) | KR20210123353A (en) |
| CN (2) | CN113645969A (en) |
| AU (2) | AU2020218496A1 (en) |
| BR (2) | BR112021015099A2 (en) |
| CA (2) | CA3128039A1 (en) |
| IL (2) | IL285187A (en) |
| MX (2) | MX2021009383A (en) |
| SG (2) | SG11202107842QA (en) |
| TW (2) | TW202045167A (en) |
| WO (2) | WO2020163245A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3186766A1 (en) | 2020-07-24 | 2022-01-27 | Danielle Combessis | Pharmaceutical compositions comprising venglustat |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (en) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| CR20190034A (en) * | 2011-03-18 | 2019-05-20 | Genzyme Corp | GLUCOSILCERAMIDE SINTASA INHIBITORS (Divisional 2013-0471) |
| CN105979945A (en) | 2013-12-11 | 2016-09-28 | 建新公司 | Glucosylceramide synthase inhibitors |
| TW201642855A (en) * | 2015-03-10 | 2016-12-16 | 健臻公司 | Methods for treating proteinopathies |
-
2020
- 2020-02-03 MX MX2021009383A patent/MX2021009383A/en unknown
- 2020-02-03 SG SG11202107842QA patent/SG11202107842QA/en unknown
- 2020-02-03 US US17/428,504 patent/US20220023273A1/en active Pending
- 2020-02-03 KR KR1020217027946A patent/KR20210123353A/en active Search and Examination
- 2020-02-03 CN CN202080025346.0A patent/CN113645969A/en active Pending
- 2020-02-03 KR KR1020217027945A patent/KR20210123352A/en active Search and Examination
- 2020-02-03 BR BR112021015099-4A patent/BR112021015099A2/en unknown
- 2020-02-03 EP EP20709405.3A patent/EP3920913A1/en active Pending
- 2020-02-03 US US17/428,505 patent/US20220016092A1/en active Pending
- 2020-02-03 JP JP2021545375A patent/JP2022520747A/en active Pending
- 2020-02-03 AU AU2020218496A patent/AU2020218496A1/en active Pending
- 2020-02-03 AU AU2020217659A patent/AU2020217659A1/en active Pending
- 2020-02-03 EP EP20709406.1A patent/EP3920914A1/en active Pending
- 2020-02-03 CA CA3128039A patent/CA3128039A1/en active Pending
- 2020-02-03 SG SG11202107844UA patent/SG11202107844UA/en unknown
- 2020-02-03 BR BR112021015172-9A patent/BR112021015172A2/en unknown
- 2020-02-03 CN CN202080025266.5A patent/CN113710249A/en active Pending
- 2020-02-03 WO PCT/US2020/016441 patent/WO2020163245A1/en unknown
- 2020-02-03 WO PCT/US2020/016440 patent/WO2020163244A1/en unknown
- 2020-02-03 JP JP2021545383A patent/JP2022519274A/en active Pending
- 2020-02-03 CA CA3128041A patent/CA3128041A1/en active Pending
- 2020-02-03 MX MX2021009384A patent/MX2021009384A/en unknown
- 2020-02-04 TW TW109103397A patent/TW202045167A/en unknown
- 2020-02-04 TW TW109103398A patent/TW202045168A/en unknown
-
2021
- 2021-07-28 IL IL285187A patent/IL285187A/en unknown
- 2021-08-02 IL IL285304A patent/IL285304A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220023273A1 (en) | 2022-01-27 |
| KR20210123352A (en) | 2021-10-13 |
| AU2020217659A1 (en) | 2021-08-26 |
| WO2020163244A1 (en) | 2020-08-13 |
| EP3920913A1 (en) | 2021-12-15 |
| AU2020218496A1 (en) | 2021-08-26 |
| CA3128041A1 (en) | 2020-08-13 |
| EP3920914A1 (en) | 2021-12-15 |
| BR112021015172A2 (en) | 2021-09-28 |
| JP2022520747A (en) | 2022-04-01 |
| BR112021015099A2 (en) | 2021-10-05 |
| JP2022519274A (en) | 2022-03-22 |
| WO2020163245A1 (en) | 2020-08-13 |
| CN113645969A (en) | 2021-11-12 |
| KR20210123353A (en) | 2021-10-13 |
| CN113710249A (en) | 2021-11-26 |
| MX2021009384A (en) | 2021-09-10 |
| CA3128039A1 (en) | 2020-08-13 |
| IL285187A (en) | 2021-09-30 |
| TW202045168A (en) | 2020-12-16 |
| US20220016092A1 (en) | 2022-01-20 |
| SG11202107842QA (en) | 2021-08-30 |
| IL285304A (en) | 2021-09-30 |
| TW202045167A (en) | 2020-12-16 |
| MX2021009383A (en) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016037157A3 (en) | Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | |
| IL259422A (en) | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms | |
| IL269174A (en) | Methods for treating complement-mediated diseases and disorders | |
| PL3405215T3 (en) | Methods for the treatment of danon disease and other disorders of autophagy | |
| EP3570670A4 (en) | Compositions and methods for treating lysosomal storage diseases and disorders | |
| EP3826684A4 (en) | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same | |
| EP3464378A4 (en) | Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders | |
| EP4076422A4 (en) | Methods for improving neurological diseases and disorders | |
| ZA202002991B (en) | Methods and compositions for assessing and treating intraocular diseases and disorders | |
| IL285627A (en) | Systems and methods for the treatment of symptoms associated with migraines | |
| IL286268A (en) | Pridopidine for use in the treatment of mitochondrial associated diseases and disorders, including symptoms thereof | |
| IL275985A (en) | Compositions and methods for treating retinal disorders | |
| IL255612A (en) | Methods for diagnosing and assessing treatment for cushing's syndrome | |
| IL285304A (en) | Methods for treating symptoms and disorders associated with lysosomal storage diseases | |
| WO2015061777A3 (en) | Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema | |
| IL283271A (en) | Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders | |
| EP3313386A4 (en) | Methods and compositions for treating lysosomal storage disorders | |
| EP3625248A4 (en) | Compositions and methods for diagnosing and treating diseases and disorders associated with mutant kcnj5 | |
| EP4010075A4 (en) | Methods for the treatment of apoc3-related diseases and disorders | |
| SG11202002692XA (en) | Azabicyclo and diazepine derivatives for treating ocular disorders | |
| EP3639854A4 (en) | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof | |
| EP3448415A4 (en) | Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage | |
| EP3481432A4 (en) | Diagnosing col6-related disorders and methods for treating same | |
| IL283031A (en) | Vibegron for the treatment of overactive bladder symptoms | |
| IL276042A (en) | Therapies and methods to treat tlr2-mediated diseases and disorders |